| | *Sponsored by Nutriband Inc.
Krypton Street Announces Coverage On Nutriband Inc. (NASDAQ: NTRB) — Starting This Morning—Wednesday, April 30, 2025.
Here’s What We Can Tell You—Right Now…
There’s Under 5.2M Shares Listed In The Float—Which Signals The Potential For Significant Swings If A Shift In Demand Occurs.
(NTRB) Is Currently Trending Above Its 5-Day ($5.46) And 20-Day ($5.22) Moving Averages—Which Could Show The Potential For Bullish Momentum.
One Analyst From Noble Capital, Robert Leboyer, Set A $13 Target On (NTRB), Which Suggests 150% Upside Potential From Yesterday’s $5.60 Open.
Pull Up (NTRB) Before The Bell Rings…
April 30, 2025
Dear Reader,
Pull up (NTRB) before the bell rings.
There’s about 15 minutes to go.
A tiny biotech is taking on the opioid crisis with a groundbreaking patch that could stop abuse in its tracks.
This isn’t just science—it’s a mission to save lives!
Nutriband Inc. (NASDAQ: NTRB), led by CEO Gareth Sheridan and his tight-knit team, is behind AVERSA™, a game-changer in pain management.
With only 5.2M shares in its float, the potential for big swings is entirely possible.
It’s trending above its 5-day ($5.46) and 20-day ($5.22) averages, and Noble Capital’s $13 target suggests 150% upside potential from yesterday’s $5.60 open. | | Buckle up—here’s why (NTRB) is topping our watchlist this morning, April 30, 2025! Momentum has been building fast, and the latest developments only reinforce why this name continues to rise through the ranks.
From breakthrough innovation to global expansion, this company is stacking milestones worth paying close attention to.
Why Nutriband Stands Out
Strong Patents Around the World: (NTRB)’s AVERSA™ technology, which prevents opioid and stimulant abuse, is protected by patents in 46 countries.
On February 7, 2025, the U.S. Patent Office approved a new patent (application 18/369,241) for AVERSA™, making its U.S. protection even stronger.
On April 11, 2025, a patent in Macao (number J/9010) added to this global shield, covering countries like the U.S., Europe, Japan, and China.
These patents, good until 2035, protect AVERSA™ fen-tan-yl, Buprenorphine, and Methylphenidate, making (NTRB) a leader in safe transdermal products.
Major Partnership with Kindeva: On February 13, 2025, Nutriband teamed up with Kindeva top expert in dr-ug-device systems.
This exclusive deal combines Kindeva’s FDA-approved fen-tan-yl patch with (NTRB)’s AVERSA™ technology, aiming for an FDA investigational (IND) filing by mid-2025. | | The partnership splits costs and includes milestone payments, helping Nutriband move faster toward launching the world’s first abuse-deterrent fen-tan-yl patch.
Big Market Potential: Health Advances, a trusted healthcare consulting firm, predicts AVERSA™ fen-tan-yl could earn $80–200M in peak U.S. sales, thanks to its competitive price compared to other fen-tan-yl patches.
AVERSA™ Buprenorphine, another potential first-of-its-kind product, could bring in $70–130M yearly. These numbers, based on 2022 and 2023 research, show a huge need for safer pain management, backed by 2022 CDC opioid guidelines.
Solid Fiscal Position: (NTRB) has a strong financial foundation. As of October 31, 2024, it had $5.7M in cash and $12.55M in total assets, with only $1.32M in liabilities.
This means Nutriband can keep funding its projects and hit important FDA goals without fiscal stress.
Smart Branding Moves: On April 4, 2025, (NTRB) partnered with Charlotte FC, a Major League Soccer team, to promote its AI Tape and AVERSA™ brands. Based in its North Carolina facility, this deal boosts Nutriband’s visibility and ties it to the local community.
On February 11, 2025, Olympic silver medalist Anastasia Nichita joined Nutriband’s Product Advisory Board to help grow its consumer products, like AI Tape, a kinesiology tape with healing ingredients.
Behind the Scenes: A Leader’s Clear Vision: In a December 2024 letter to shareholders, CEO Gareth Sheridan shared his passion: “Your support drives our mission to make patients safer with innovative transdermal technology.”
He highlighted the Kindeva partnership as a key step for AVERSA™ fen-tan-yl, which could change how opioids are used safely.
Sheridan also noted that Nutriband might skip Phase 2 and 3 clinical trials because Kindeva’s fen-tan-yl patch is already FDA-approved, which could speed up the process.
His clear focus and confidence show a leader ready to deliver results. | | Why Nutriband Is Worth Watching: Nutriband Inc. (NASDAQ: NTRB) is a biotech leader fighting the opioid crisis with smart solutions and determination.
Its worldwide patents, strong Kindeva partnership, and $80–200M sales potential for AVERSA™ fen-tan-yl show a company ready to shine.
Here’s 7 Reasons Why Nutriband Inc. (NASDAQ: NTRB) is Topping Our Watchlist This Morning…
1. Low Float: With a float of under 5.2M shares, (NTRB)’s low availability could lead to the potential for significant volatility and big swings if demand starts to shift.
2. Analyst Coverage:Noble Capital’s Robert Leboyer set a $13 target, which suggests a 150% upside potential from yesterday’s $5.60 open, reflecting strong confidence in (NTRB)’s growth potential.
3. Technical Strength: As of recent data, (NTRB) is trending above its 5-day ($5.46) and 20-day ($5.22) moving averages, showing short-term strength, though it remains below its 50-day average ($6.14), hinting at the potential for bullish momentum.
4. Significant Market Potential: Health Advances forecasts AVERSA™ fen-tan-yl could achieve $80–200M in peak U.S. sales and AVERSA™ Buprenorphine $70–130M annually, driven by the urgent need for safer pain management solutions, as supported by 2022 CDC opioid guidelines.
5. Key Kindeva Partnership: On February 13, 2025, (NTRB) secured an exclusive deal with Kindeva to develop AVERSA™ fen-tan-yl, targeting an FDA investigational filing by mid-2025.
6. Innovative AVERSA™ Technology: (NTRB)’s AVERSA™ transdermal patch, infused with aversive agents like Bitrex®, aims to prevent opioid misuse while delivering pain relief, positioning it as a pioneering solution in addressing the opioid crisis.
7. Extensive Patent Protection: AVERSA™ is backed by patents in 46 countries, including a U.S. patent allowance on February 7, 2025, and a Macao patent (J/9010) granted by April 11, 2025, ensuring protection through 2035 for products like AVERSA™ fen-tan-yl and Buprenorphine. | | Take A Look At (NTRB) Before The Bell Rings…
Nutriband Inc. (NASDAQ: NTRB) is carving a bold path in biotech, leveraging its AVERSA™ technology to address the opioid crisis with precision and innovation.
With a low float of under 5.2M shares, technical strength above key moving averages, and a $13 target from Noble Capital which suggests 150% upside potential, (NTRB) poised for attention.
Its global patents across 46 countries, exclusive Kindeva partnership, and Health Advances’ projections of up to $200M in peak U.S. sales for AVERSA™ fen-tan-yl underscore its potential to reshape pain management.
Nutriband Inc. (NASDAQ: NTRB) is on track for its mid-2025 FDA milestone, making it one little-known company to keep on your radar.
We have all eyes locked on (NTRB) this morning.
Dive in and start your research on (NTRB) before the bell rings.
My next update could be out shortly—keep a lookout for it. | |
Sincerely,
Alex Ramsay Co-Founder / Managing Editor Krypton Street Newsletter | KryptonStreet.com (“KryptonStreet” or “KS” ) is owned by Media 1717 LLC, a single member limited liability company. Data is provided from third-party sources and KryptonStreet is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile KS brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors.
The owner of Media 1717 LLC owns and operates kryptonstreet . com (“KS”). From time to time, KS will publicly disseminate information about a company via website, email, SMS and other points of media.
*Pursuant to an agreement between Media 1717 LLC and TD Media LLC, Media 1717 LLC has been hired for a period beginning on 04/29/2025 and ending on 04/30/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Media 1717 LLC has been paid seven thousand five hundred USD (“Funds”). To date, including under the previously described agreement, Media 1717 LLC has been paid thirty thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Media 1717 LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://kryptonstreet.com/disclosure/ntrb-ybhl5/#details | | | | |
Tidak ada komentar:
Posting Komentar